AER 1515355 is a spontaneous case, received on 29/Dec/2014 from a consumer (patient husband) via company 
representative and concerns a 66 year old female patient who developed progressive multifocal 
leukoencephalopathy (PML), low immunity disease, pain in heart and lost 20-25% of grey matter in cerebellum 
while being treated with rituximab (Rituxan).
The patient's medical history included lupus and thyroid issue. Her concurrent condition included blood pressure. 
Past drug included erythromycin (allergy: makes her go blind). Concomitant medications included unspecified blood
pressure medication (blood pressure), unspecified thyroid medication (thyroid issue) and pramipexole 
hydrochloride.
In Nov/2012, the patient started intravenous rituximab for (dose, frequency and form not reported) for lymphoma 
cancer. On an unspecified date in /Nov/2012 her peripherally inserted central catheter (PICC) line was pulled out, 
after that she experienced pain in her heart. She was diagnosed with progressive multifocal leukoencephalopathy 
(PML), low immunity disease, and lost 20-25% of grey matter in cerebellum. In /Jan/2014, the therapy with 
rituximab was discontinued and the event lost 20-25% of grey matter in cerebellum resolved.
At the time of this report, the outcome for the events progressive multifocal leukoencephalopathy (PML), low 
immunity disease, pain heart was not reported.
The reporter did not assess the causal relationship for the events progressive multifocal leukoencephalopathy 
(PML), low immunity disease, pain heart and lost 20-25% of grey matter in cerebellum to rituximab.
The company assess the event lost 20-25% of grey matter in cerebellum, and progressive multifocal 
leukoencephalopathy as medically significant.
No further information was provided.